Table 1.
Demographic and clinical characteristics of brain metastases cohort.
| Clinical subtype | ER+/HER2− | HER2+ | TNBC |
|---|---|---|---|
| Number of patients | 13 | 16 | 16 |
| Age at diagnosis* | 53 [40, 63] | 50 [26, 67] | 46 [26, 66] |
| Age group (%) | |||
| <40 | 0 (0.0) | 4 (25.0) | 5 (31.2) |
| 40–59 | 10 (76.9) | 9 (56.2) | 8 (50.0) |
| ≥60 | 3 (23.1) | 3 (18.8) | 3 (18.8) |
| Vital status (%) | |||
| Alive | 1 (7.7) | 1 (6.2) | 2 (12.5) |
| Dead | 12 (92.3) | 15 (93.8) | 14 (87.5) |
| Overall survival* | 74 [32, 223] | 58 [18, 225] | 42 [18, 173] |
| BMFS* | 53 [12, 216] | 31 [5, 151] | 25 [13, 89] |
| SPBM* | 18 [5, 65] | 22 [3, 74] | 12 [3, 147] |
| Other metastases (%) | |||
| Yes | 10 (76.9) | 10 (62.5) | 8 (50.0) |
| No | 3 (23.1) | 6 (37.5) | 8 (50.0) |
| Histological subtype (%) | |||
| IDC | 11 (84.6) | 12 (75.0) | 16 (100.0) |
| ILC | 1 (7.7) | 1 (6.2) | 0 (0.0) |
| Other | 1 (7.7) | 3 (18.8) | 0 (0.0) |
| PAM50 subtype (%) | |||
| LumA | 7 (53.8) | 3 (18.8) | 1 (6.2) |
| LumB | 3 (23.1) | 5 (31.2) | 0 (0.0) |
| Her2 | 0 (0.0) | 8 (50.0) | 1 (6.2) |
| Basal | 2 (15.4) | 0 (0.0) | 14 (87.5) |
| Normal | 1 (7.7) | 0 (0.0) | 0 (0.0) |
BMFS brain metastases-free survival in months (time from primary breast diagnosis to brain metastatic disease diagnosis), SPBM survival post brain metastases in months (time from brain metastases diagnosis to death or follow up), IDC invasive ductal carcinoma, ILC invasive lobular carcinoma,
*Median [min, max].